4β-Hydroxywithanolide E
(Synonyms: 4BETA-羟基醉茄内酯E) 目录号 : GC45354A withanolide with anti-inflammatory and anticancer activities
Cas No.:54334-04-2
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
4β-Hydroxywithanolide E is a withanolide steroidal lactone that has been found in P. peruviana and has anti-inflammatory and anticancer activities.1,2,3 It inhibits LPS-induced nitric oxide (NO) production in RAW 264.7 cells and TNF-α-induced NF-κB activity in HEK293 cells (IC50s = 0.32 and 0.04 μM, respectively).1 4β-Hydroxywithanolide E (5 μM) inhibits LPS-induced increases in inducible nitric oxide synthase (iNOS) and COX-2 levels and Akt and STAT1 phosphorylation in RAW 264.7 cells.2 It inhibits Wnt signaling in HCT116 and SW480 colorectal cancer cells (IC50s = 1.85 and 2.67 μM, respectively).3 4β-Hydroxywithanolide E inhibits the proliferation of HCT116, SW480, HT-29, and LoVo cells (IC50s = 0.24-0.51 μM). It halts the cell cycle at the G0/G1 phase in HCT116 and HT-29 cells and induces apoptosis in HCT116 and SW480 cells in a concentration-dependent manner. 4β-Hydroxywithanolide E (10 mg/kg per day for 14 days) reduces tumor growth in an HCT116 mouse xenograft model.
References
1. Sang-Ngern, M., Youn, U.J., Park, E.J., et al. Withanolides derived from Physalis peruviana (Poha) with potential anti-inflammatory activity. Bioorg. Med. Chem. Lett. 26(12), 2755-2759 (2016).
2. Park, E.J., Sang-Ngern, M., Chang, L.C., et al. Physalactone and 4β-hydroxywithanolide E isolated from Physalis peruviana inhibit LPS-induced expression of COX-2 and iNOS accompanied by abatement of Akt and STAT1. J. Nat. Prod. 82(3), 492-499 (2019).
3. Ye, Z.N., Yuan, F., Liu, J.Q., et al. Physalis peruviana-derived 4β-hydroxywithanolide E, a novel antagonist of Wnt signaling, inhibits colorectal cancer in vitro and in vivo. Molecules 24(6), E1146 (2019).
Cas No. | 54334-04-2 | SDF | |
别名 | 4BETA-羟基醉茄内酯E | ||
Canonical SMILES | O=C1[C@@]2(C)[C@@]([C@H]3C[C@]4([H])[C@]2([H])CC[C@@]5(C)[C@@]4(O)CC[C@@]5(O)[C@@](C)(O)[C@@]6([H])CC(C)=C(C)C(O6)=O)(O3)[C@@H](O)C=C1 | ||
分子式 | C28H38O8 | 分子量 | 502.6 |
溶解度 | Chloroform: soluble,Ethanol: soluble,Methanol: soluble | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.9897 mL | 9.9483 mL | 19.8965 mL |
5 mM | 0.3979 mL | 1.9897 mL | 3.9793 mL |
10 mM | 0.199 mL | 0.9948 mL | 1.9897 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。